Denosumab (Prolia)

Denosumab (Prolia) is covered only for FDA‑approved non‑oncology osteoporosis indications (postmenopausal women, men, and glucocorticoid‑induced osteoporosis); oncology uses are excluded. Approval requires documented high fracture risk, prior failure/inadequate response to a 12‑month oral bisphosphonate or trial of an IV bisphosphonate (or intolerance/contraindication to bisphosphonates; a prior fragility fracture waives the bisphosphonate trial), documentation of systemic glucocorticoid use for GIOP when applicable, and is limited to 12 months at up to 60 mg subcutaneously every 6 months.

"Treatment of osteoporosis in postmenopausal women"

Sign up to see full coverage criteria, indications, and limitations.